The Notice states that an abstract of the technical disclosure is required. In response, Applicant submits herewith a Preliminary Amendment including an abstract in compliance with 37 CFR § 1.72(b). The abstract is based on that submitted in parent U.S. application Ser. No. 15/556,084 (issued as U.S. Pat. No. 11,193,106) and international application no. PCT/US2016/020621, of which U.S. application Ser. No. 15/556,084 is the US national stage application. The submitted abstract differs from the abstract of the parent application only by a correction of “may further comprising” to “may further comprise”. Thus, the abstract contains no new matter.

The Notice states that an abstract of the technical disclosure is required. In response, Applicant submits herewith a Preliminary Amendment including an abstract in compliance with 37 CFR § 1.72(b). The abstract is based on that submitted in parent U.S. application Ser. No. 15/556,084 (issued as U.S. Pat. No. 11,193,106) and international application no. PCT/US2016/020621, of which U.S. application Ser. No. 15/556,084 is the US national stage application. The submitted abstract differs from the abstract of the parent application only by a correction of “may further comprising” to “may further comprise”. Thus, the abstract contains no new matter.

Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.

Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.

##STR00001##

The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD). ##STR00001##

The present invention discloses the preparation method of cis-p-menthane-1,8-di-secondary amine compounds and their application in weed control. The preparation method is as follows: cis-p-menthane-1,8-di-Schiff base compounds are used as the raw material, and the reducing agent is added in batches into the raw material in a polar organic solvent at −10˜50° C. to react for 1˜24 h; after the reaction is complete, the reaction solution is quenched with distilled water and extracted with dichloromethane, and the extract phase is dried with anhydrous sodium sulfate, filtered with a filter and then distilled under reduced pressure to obtain crude cis-p-menthane-1,8-di-secondary amine compounds, which are purified into the pure product through recrystallization or silica gel column chromatography. The Petri dish seed germination method is used to determine the root and stem growth inhibition levels of barnyard grass incubated under different concentrations of cis-p-menthane-1,8-di-secondary amine compounds to evaluate the herbicidal activity of the compounds.

Disclosed herein are compounds, salts, solvates of Formula (1), and any formulation thereof. Also disclosed are methods of eliciting hydraulic enhancement and/or increasing yield of a plant by contacting a plant with compounds, salts, solvates of Formula (1), or any formulation thereof.